MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas

S. Tura, F. Mandelli, P. Mazza, S. Pileri, F. Gherlinzoni, M. Bocchia, P. L. Zinzani, M. Fiacchini, M. Martelli, G. Papa, M. Antimi, M. F. Martelli, F. Grignani, B. Falini, F. Calabresi, E. M. Ruggeri, F. Dammacco, V. M. Lauta, G. Lucarelli, L. Moretti

Research output: Contribution to journalArticlepeer-review

Abstract

From September 1988 two hundred -sixty - seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus F-MACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse- free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs, 42%). The degree Of hemathological and non-hematological toxicity was similar in both regimens. More reliable conclusions will be drawn after a longer follow-up.

Original languageEnglish
Pages (from-to)74-78
Number of pages5
JournalLeukemia
Volume5
Issue numberSUPPL. 1
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint Dive into the research topics of 'MACOP-B vs F. MACHOP in the treatment of high-grade Non-Hodgkin's lymphomas'. Together they form a unique fingerprint.

Cite this